BioTE Medical is a leader in Precision and Preventive Medicine. We create patient-centric strategies that optimize hormones for women and men.

About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´s lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML can overcome this challenge by reconstituting normal RTK signaling in the tumor.www.papyrustherapeutics.com

Origami Surgical has developed the StitchKit® technology, a unique patented portfolio engineered to enhance robotic-assisted surgery by allowing the surgeon to manage all aspects of suture use and needle disposal in clear view. The StitchKit® is a single use device, designed to pass multiple strands of suture with attached needles into the surgery site at once. The delivery and retrieval design is intended to improve safety, autonomy, and surgical efficiency.

LumeNXT LLC, in collaboration with Medtronic (NYSE:MDT), is a privately held surgical device company pioneering the utilization of non-tethered light emitting diode (LED) illumination. This proprietary technology is the only battery driven light emitting diode technology currently available on the market. LumeNXT's advanced technology possesses many advantages over the current options available in the marketplace. Leveraging our strong patents and intellectual property, LumeNXT is uniquely designed to create safe, effective, and versatile illumination.Our focus is dedicated to developing minimally invasive, clinically valuable solutions designed to deliver illumination to multiple surgical sites without the need for a surgical outlet. Additionally, the non-tethered posture allows for illumination to be attached to any surgical device in order to complement standard operating room instruments. https://lumenxt.com/

Founded in 2016, Renovia Inc. was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Through its proprietary medical device technology and app enabled visualization of pelvic movement, Renovia is developing a product pipeline with the potential to better diagnose and treat women affected by urinary incontinence and other pelvic floor disorders. Renovia’s existing FDA-cleared device, the leva® Pelvic Digital Health System, is indicated for strengthening pelvic floor muscles, and indicated for treating stress, mixed and mild to moderate urgency urinary incontinence in women. The leva device and Renovia’s full product pipeline all leverage state-of-the-art patient-based apps and data management technology to provide precise, cost-effective treatment of weakened pelvic floor muscles in real-time, while collecting actionable compliance and progress data on women’s pelvic health. Urinary incontinence affects an estimated 20 million women in the U.S. and an estimated 250 million women worldwide. As a women's health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health. https://renoviainc.com/

Minerva Neurosciences (NASDAQ:NERV) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Learn more at: https://minervaneurosciences.com/

Good Start Genetics, acquired by Invitae Corporation (NYSE:NVTA), is an information solutions company delivering best-in-class genetics offerings to growing families. Learn more at: https://www.goodstartgenetics.com/about-us/board-of-directors/

Myolex, Inc. is developing and validating muscle assessment devices for neuro-muscular disease clinical trial applications and the high performing athletic market. Learn more at: https://www.myolex.com

Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases. The Company’s first marketed product, JUXTAPID™ (lomitapide) was approved by the U.S. Food and Drug Administration in December 2012 for the treatment of homozygous familial hypercholesterolemia (HoFH).

ViaCell, Inc. (NASDAQ: VIAC) was a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company developed a pipeline of proprietary product candidates intended to address cancer, cardiac disease, diabetes and infertility. ViaCell's portfolio of proprietary technologies included Selective Amplification technology and USSCs.